{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:26:57Z","timestamp":1781220417087,"version":"3.54.1"},"reference-count":118,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R43AI136220"],"award-info":[{"award-number":["R43AI136220"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>In the midst of the ongoing COVID-19 coronavirus pandemic, influenza virus remains a major threat to public health due to its potential to cause epidemics and pandemics with significant human mortality. Cases of H7N9 human infections emerged in eastern China in 2013 and immediately raised pandemic concerns as historically, pandemics were caused by the introduction of new subtypes into immunologically na\u00efve human populations. Highly pathogenic H7N9 cases with severe disease were reported recently, indicating the continuing public health threat and the need for a prophylactic vaccine. Here we review the development of recombinant influenza virus-like particles (VLPs) as vaccines against H7N9 virus. Several approaches to vaccine development are reviewed including the expression of VLPs in mammalian, plant and insect cell expression systems. Although considerable progress has been achieved, including demonstration of safety and immunogenicity of H7N9 VLPs in the human clinical trials, the remaining challenges need to be addressed. These challenges include improvements to the manufacturing processes, as well as enhancements to immunogenicity in order to elicit protective immunity to multiple variants and subtypes of influenza virus.<\/jats:p>","DOI":"10.3390\/v12050518","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T11:26:00Z","timestamp":1588937160000},"page":"518","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development"],"prefix":"10.3390","volume":"12","author":[{"given":"Peter","family":"Pushko","sequence":"first","affiliation":[{"name":"Medigen, Inc., 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Tretyakova","sequence":"additional","affiliation":[{"name":"Medigen, Inc., 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.1257622","article-title":"Virus sharing, genetic sequencing, and global health security","volume":"345","author":"Gostin","year":"2014","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"185ra68","DOI":"10.1126\/scitranslmed.3006368","article-title":"Synthetic generation of influenza vaccine viruses for rapid response to pandemics","volume":"5","author":"Dormitzer","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mostafa, A., Abdelwhab, E.M., Mettenleiter, T.C., and Pleschka, S. (2018). Zoonotic Potential of Influenza A Viruses: A Comprehensive Overview. Viruses, 10.","DOI":"10.3390\/v10090497"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Philippon, D.A.M., Wu, P., Cowling, B.J., and Lau, E.H.Y. (2020). Avian influenza human infections at the human-animal interface. J. Infect. Dis.","DOI":"10.1093\/infdis\/jiaa105"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11684-020-0739-z","article-title":"Research progress on human infection with avian influenza H7N9","volume":"14","author":"Wu","year":"2020","journal-title":"Front. Med."},{"key":"ref_6","first-page":"359","article-title":"Evolution and ecology of influenza A viruses","volume":"385","author":"Yoon","year":"2014","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza A (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijid.2015.01.013","article-title":"Isolation and characteristic analysis of a novel strain H7N9 of avian influenza virus A from a patient with influenza-like symptoms in China","volume":"33","author":"Chen","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1073\/pnas.1422456112","article-title":"Evolution of the H9N2 influenza genotype that facilitated the genesis of the novel H7N9 virus","volume":"112","author":"Pu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3201\/eid2104.141703","article-title":"Influenza A(H7N9) Virus Transmission between Finches and Poultry","volume":"21","author":"Jones","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1038\/ncomms7553","article-title":"Mammalian adaptation of influenza A(H7N9) virus is limited by a narrow genetic bottleneck","volume":"6","author":"Zaraket","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Yang, J.R., Kuo, C.Y., Huang, H.Y., Wu, F.T., Huang, Y.L., Cheng, C.Y., Su, Y.T., Wu, H.S., and Liu, M.T. (2015). Characterization of Influenza A (H7N9) Viruses Isolated from Human Cases Imported into Taiwan. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119792"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1900273","DOI":"10.2807\/1560-7917.ES.2019.24.21.1900273","article-title":"The re-emergence of highly pathogenic avian influenza H7N9 viruses in humans in mainland China, 2019","volume":"24","author":"Yu","year":"2019","journal-title":"Eurosurveillance"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1128\/jvi.68.9.6074-6078.1994","article-title":"Proprotein-processing endoproteases PC6 and furin both activate hemagglutinin of virulent avian influenza viruses","volume":"68","author":"Horimoto","year":"1994","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ito, M., Yamayoshi, S., Murakami, K., Saito, K., Motojima, A., Nakaishi, K., and Kawaoka, Y. (2019). Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus. Viruses, 11.","DOI":"10.3390\/v11020149"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1038\/s41598-018-22410-w","article-title":"The temporal distribution of new H7N9 avian influenza infections based on laboratory-confirmed cases in Mainland China, 2013\u20132017","volume":"8","author":"Guo","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_17","first-page":"1","article-title":"Tackling a novel lethal virus: A focus on H7N9 vaccine development","volume":"16","author":"Rudenko","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/14760584.2019.1639503","article-title":"Challenges in the development of egg-independent vaccines for influenza","volume":"18","author":"Trombetta","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0264-410X(03)00071-9","article-title":"The annual production cycle for influenza vaccine","volume":"21","author":"Gerdil","year":"2003","journal-title":"Vaccine"},{"key":"ref_20","unstructured":"WHO (2006). Department of Immunization, Vaccines and Biologicals. Geneva: Global Pandemic Influenza Action Plan to Increase Vaccine Supply 2006, WHO."},{"key":"ref_21","unstructured":"WHO (2020). Summary of Status of Development and Availability of Avian Influenza A(H7N9) Candidate Vaccine Viruses and Potency Testing Reagents, WHO."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1016\/j.vaccine.2017.08.047","article-title":"Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System","volume":"35","author":"Woo","year":"2017","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1089\/vim.2005.18.244","article-title":"Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge","volume":"18","author":"Galarza","year":"2005","journal-title":"Viral Immunol."},{"key":"ref_24","first-page":"269","article-title":"Influenza virus-like particles as pandemic vaccines","volume":"333","author":"Kang","year":"2009","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/JVI.00207-09","article-title":"Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge","volume":"83","author":"Perrone","year":"2009","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1016\/j.vaccine.2007.01.106","article-title":"Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin","volume":"25","author":"Bright","year":"2007","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1016\/j.vaccine.2005.07.098","article-title":"Influenza virus-like particles comprised of the, H.A.; NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB\/c mice","volume":"23","author":"Pushko","year":"2005","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Quan, F.S., Vunnava, A., Compans, R.W., and Kang, S.M. (2010). Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009161"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ross, T.M., Mahmood, K., Crevar, C.J., Schneider-Ohrum, K., Heaton, P.M., and Bright, R.A. (2009). A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006032"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1016\/j.vaccine.2014.07.074","article-title":"Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process","volume":"32","author":"Buckland","year":"2014","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.vaccine.2015.03.009","article-title":"Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets","volume":"33","author":"Liu","year":"2015","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.virol.2017.06.006","article-title":"Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets","volume":"509","author":"Smith","year":"2017","journal-title":"Virology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1016\/j.vaccine.2015.08.005","article-title":"Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge","volume":"33","author":"Kamlangdee","year":"2015","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6714","DOI":"10.1038\/ncomms7714","article-title":"Human monoclonal antibodies targeting the haemagglutinin glycoprotein can neutralize H7N9 influenza virus","volume":"6","author":"Chen","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Schmeisser, F., Vasudevan, A., Verma, S., Wang, W., Alvarado, E., Weiss, C., Atukorale, V., Meseda, C., and Weir, J.P. (2015). Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0117108"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1080\/21645515.2018.1460297","article-title":"Cell culture-derived flu vaccine: Present and future","volume":"14","author":"Eiros","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1128\/JVI.03095-13","article-title":"Divergent H7 immunogens offer protection from H7N9 virus challenge","volume":"88","author":"Krammer","year":"2014","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/j.vaccine.2015.07.026","article-title":"Recombinant H7 Hemagglutinin Forms Subviral Particles that Protect Mice and Ferrets from Challenge with H7N9 Influenza Virus submitted for publication","volume":"33","author":"Pushko","year":"2015","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1016\/j.vaccine.2015.09.065","article-title":"Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets","volume":"33","author":"Pillet","year":"2015","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.vaccine.2013.11.036","article-title":"One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge","volume":"32","author":"Klausberger","year":"2014","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e01044","DOI":"10.1128\/mBio.01044-15","article-title":"An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus","volume":"6","author":"Schwartzman","year":"2015","journal-title":"MBio"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1016\/j.vaccine.2013.07.043","article-title":"Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A\/Anhui\/1\/2013 (H7N9) protection and heterologous A\/chicken\/Jalisco\/CPA1\/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus","volume":"31","author":"Smith","year":"2013","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.3390\/v7082821","article-title":"Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB\/C Mice","volume":"7","author":"Zhang","year":"2015","journal-title":"Viruses"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1016\/j.vaccine.2016.03.031","article-title":"Hemagglutinin amino acids related to receptor specificity could affect the protection efficacy of H5N1 and H7N9 avian influenza virus vaccines in mice","volume":"34","author":"Xu","year":"2016","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Hu, C.J., Chien, C.Y., Liu, M.T., Fang, Z.S., Chang, S.Y., Juang, R.H., Chang, S.C., and Chen, H.W. (2017). Multi-antigen avian influenza a (H7N9) virus-like particles: Particulate characterizations and immunogenicity evaluation in murine and avian models. BMC Biotechnol., 17.","DOI":"10.1186\/s12896-016-0321-6"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.intimp.2017.12.020","article-title":"Intramuscular and intranasal immunization with an H7N9 influenza virus-like particle vaccine protects mice against lethal influenza virus challenge","volume":"58","author":"Ren","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.virol.2016.12.001","article-title":"Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens","volume":"501","author":"Pushko","year":"2017","journal-title":"Virology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2019.02.004","article-title":"Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development","volume":"164","author":"Hong","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Kang, H.J., Chu, K.B., Lee, D.H., Lee, S.H., Park, B.R., Kim, M.C., Kang, S.M., and Quan, F.S. (2019). Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216871"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.virol.2013.03.027","article-title":"Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses","volume":"442","author":"Tretyakova","year":"2013","journal-title":"Virology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.4049\/jimmunol.178.4.2361","article-title":"Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN","volume":"178","author":"Rueda","year":"2007","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9134","DOI":"10.1128\/JVI.00050-06","article-title":"Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses","volume":"80","author":"Buonaguro","year":"2006","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.virol.2006.12.014","article-title":"Human immunodeficiency virus-like particles activate multiple types of immune cells","volume":"362","author":"Sailaja","year":"2007","journal-title":"Virology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1126\/science.8248784","article-title":"The influence of antigen organization on B cell responsiveness","volume":"262","author":"Bachmann","year":"1993","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"10342","DOI":"10.1038\/s41598-018-28700-7","article-title":"Structural analysis of influenza vaccine virus-like particles reveals a multicomponent organization","volume":"8","author":"McCraw","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"19123","DOI":"10.1073\/pnas.0607614103","article-title":"Influenza virus pleiomorphy characterized by cryoelectron tomography","volume":"103","author":"Harris","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Buffin, S., Peubez, I., Barriere, F., Nicolai, M.C., Tapia, T., Dhir, V., Forma, E., Seve, N., and Legastelois, I. Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies. Vaccine, 2019.","DOI":"10.1016\/j.vaccine.2019.09.057"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2019.07.057","article-title":"Characterization of influenza H1N1 Gag virus-like particles and extracellular vesicles co-produced in HEK-293SF","volume":"37","author":"Fulton","year":"2019","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.vaccine.2016.04.089","article-title":"Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate","volume":"34","author":"Gilbert","year":"2016","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.vaccine.2017.06.024","article-title":"Process intensification for high yield production of influenza H1N1 Gag virus-like particles using an inducible HEK-293 stable cell line","volume":"35","author":"Simoneau","year":"2017","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Thompson, C.M., Petiot, E., Mullick, A., Aucoin, M.G., Henry, O., and Kamen, A.A. (2015). Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems. BMC Biotechnol., 15.","DOI":"10.1186\/s12896-015-0152-x"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1021\/acssynbio.9b00111","article-title":"Enhancing the Yield and Quality of Influenza Virus-like Particles (VLPs) Produced in Insect Cells by Inhibiting Cytopathic Effects of Matrix Protein M2","volume":"8","author":"Zak","year":"2019","journal-title":"ACS Synth. Biol."},{"key":"ref_63","first-page":"287","article-title":"Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza Virus","volume":"6","author":"Li","year":"2015","journal-title":"J. Vaccines Vaccin."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.antiviral.2014.06.017","article-title":"Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes","volume":"109","author":"Prabakaran","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00705-018-04142-4","article-title":"Recombinant baculovirus vaccine expressing hemagglutinin of H7N9 avian influenza virus confers full protection against lethal highly pathogenic H7N9 virus infection in chickens","volume":"164","author":"Hu","year":"2019","journal-title":"Arch. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1016\/j.vaccine.2017.07.012","article-title":"Plant-made virus-like particles bearing influenza hemagglutinin (HA) recapitulate early interactions of native influenza virions with human monocytes\/macrophages","volume":"35","author":"Makarkov","year":"2017","journal-title":"Vaccine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.vaccine.2018.02.106","article-title":"Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy","volume":"36","author":"Lindsay","year":"2018","journal-title":"Vaccine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/pbi.12301","article-title":"Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants","volume":"13","author":"Mercier","year":"2015","journal-title":"Plant Biotechnol. J."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Holtz, K.M., Robinson, P.S., Matthews, E.E., Hashimoto, Y., McPherson, C.E., Khramtsov, N., Reifler, M.J., Meghrous, J., Rhodes, D.G., and Cox, M.M. (2014). Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevents cross-linked multimer formation and potency loss. BMC Biotechnol., 14.","DOI":"10.1186\/s12896-014-0111-y"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1128\/JVI.75.13.6154-6165.2001","article-title":"Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins","volume":"75","author":"Latham","year":"2001","journal-title":"J. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1016\/j.vaccine.2011.06.068","article-title":"Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes","volume":"29","author":"Pushko","year":"2011","journal-title":"Vaccine"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1743-422X-10-141","article-title":"Analytical technologies for influenza virus-like particle candidate vaccines: Challenges and emerging approaches","volume":"10","author":"Thompson","year":"2013","journal-title":"Virol. J."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Marcelin, G., DuBois, R., Rubrum, A., Russell, C.J., McElhaney, J.E., and Webby, R.J. (2011). A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0026335"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.virol.2012.05.006","article-title":"Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection","volume":"430","author":"Quan","year":"2012","journal-title":"Virology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fimmu.2017.00226","article-title":"Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines","volume":"8","author":"Gomes","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/vim.2013.0013","article-title":"Mucosal adjuvants for influenza virus-like particle vaccine","volume":"26","author":"Quan","year":"2013","journal-title":"Viral Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"9081","DOI":"10.1016\/j.vaccine.2011.09.051","article-title":"Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice","volume":"29","author":"Giles","year":"2011","journal-title":"Vaccine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"106013","DOI":"10.1016\/j.intimp.2019.106013","article-title":"Long-lasting protective immunity against H7N9 infection is induced by intramuscular or CpG-adjuvanted intranasal immunization with the split H7N9 vaccine","volume":"78","author":"Zhou","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1056\/NEJMc1313186","article-title":"A recombinant viruslike particle influenza A (H7N9) vaccine","volume":"369","author":"Fries","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1016\/j.vaccine.2015.06.047","article-title":"ISCOMATRIX adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans","volume":"33","author":"Chung","year":"2015","journal-title":"Vaccine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/21645515.2018.1515454","article-title":"Comparative effectiveness of H7N9 vaccines in healthy individuals","volume":"15","author":"Zheng","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clim.2016.03.008","article-title":"A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults","volume":"168","author":"Pillet","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.virol.2015.10.007","article-title":"Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein","volume":"487","author":"Tretyakova","year":"2016","journal-title":"Virology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1016\/j.vaccine.2016.09.012","article-title":"Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model","volume":"34","author":"Pushko","year":"2016","journal-title":"Vaccine"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1016\/j.vaccine.2018.05.092","article-title":"Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone","volume":"36","author":"Pushko","year":"2018","journal-title":"Vaccine"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.vaccine.2019.10.083","article-title":"Off-target effects of an insect cell-expressed influenza HA-pseudotyped Gag-VLP preparation in limiting postinfluenza Staphylococcus aureus infections","volume":"38","author":"Klausberger","year":"2020","journal-title":"Vaccine"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.1128\/JVI.01085-13","article-title":"Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin","volume":"87","author":"Goff","year":"2013","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1128\/JVI.00031-15","article-title":"Newcastle Disease Virus-Vectored H7 and H5 Live Vaccines Protect Chickens from Challenge with H7N9 or H5N1 Avian Influenza Viruses","volume":"89","author":"Liu","year":"2015","journal-title":"J. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1016\/j.vaccine.2017.10.010","article-title":"Newcastle disease virus (NDV) recombinant expressing the hemagglutinin of H7N9 avian influenza virus protects chickens against NDV and highly pathogenic avian influenza A (H7N9) virus challenges","volume":"35","author":"Hu","year":"2017","journal-title":"Vaccine"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Li, Z., Gabbard, J.D., Johnson, S., Dlugolenski, D., Phan, S., Tompkins, S.M., and He, B. (2015). Efficacy of a parainfluenza virus 5 (PIV5)-based H7N9 vaccine in mice and guinea pigs: Antibody titer towards HA was not a good indicator for protection. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120355"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fimmu.2015.00329","article-title":"Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 Subtype","volume":"6","author":"Mallajosyula","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"13133","DOI":"10.1073\/pnas.1414070111","article-title":"Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans","volume":"111","author":"Ellebedy","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Kazaks, A., Lu, I.N., Farinelle, S., Ramirez, A., Crescente, V., Blaha, B., Ogonah, O., Mukhopadhyay, T., de Obanos, M.P., and Krimer, A. (2017). Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates. BMC Biotechnol., 17.","DOI":"10.1186\/s12896-017-0396-8"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6464","DOI":"10.1016\/j.vaccine.2016.11.026","article-title":"Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses","volume":"34","author":"Zheng","year":"2016","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Song, L., Xiong, D., Kang, X., Yang, Y., Wang, J., Guo, Y., Xu, H., Chen, S., Peng, D., and Pan, Z. (2015). An avian influenza A (H7N9) virus vaccine candidate based on the fusion protein of hemagglutinin globular head and Salmonella typhimurium flagellin. BMC Biotechnol., 15.","DOI":"10.1186\/s12896-015-0195-z"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"7163","DOI":"10.1016\/j.vaccine.2011.05.077","article-title":"Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines","volume":"29","author":"Wei","year":"2011","journal-title":"Vaccine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2016.07.021","article-title":"Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design","volume":"133","author":"Liu","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1038\/emi.2016.51","article-title":"Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and, B","volume":"5","author":"Gong","year":"2016","journal-title":"Emerg. Microbes Infect."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12951-017-0305-2","article-title":"Nanodiamond enhances immune responses in mice against recombinant HA\/H7N9 protein","volume":"15","author":"Pham","year":"2017","journal-title":"J. Nanobiotechnol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.antiviral.2013.06.010","article-title":"Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection","volume":"99","author":"Kim","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Kim, K.H., Kwon, Y.M., Lee, Y.T., Kim, M.C., Hwang, H.S., Ko, E.J., Lee, Y., Choi, H.J., and Kang, S.M. (2018). Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus. Vaccines, 6.","DOI":"10.3390\/vaccines6040066"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.virol.2019.01.017","article-title":"Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles","volume":"529","author":"Lee","year":"2019","journal-title":"Virology"},{"key":"ref_104","first-page":"2751","article-title":"Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles","volume":"10","author":"Yong","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Ong, H.K., Yong, C.Y., Tan, W.S., Yeap, S.K., Omar, A.R., Razak, M.A., and Ho, K.L. (2019). An Influenza A Vaccine Based on the Extracellular Domain of Matrix 2 Protein Protects BALB\/C Mice Against H1N1 and H3N2. Vaccines, 7.","DOI":"10.3390\/vaccines7030091"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.molimm.2019.08.015","article-title":"Intragastric delivery of recombinant Lactococcus lactis displaying ectodomain of influenza matrix protein 2 (M2e) and neuraminidase (NA) induced focused mucosal and systemic immune responses in chickens","volume":"114","author":"Lahiri","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1016\/j.vaccine.2010.08.040","article-title":"Hemagglutinin displayed baculovirus protects against highly pathogenic influenza","volume":"28","author":"Tang","year":"2010","journal-title":"Vaccine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.virol.2019.08.001","article-title":"The Spodoptera frugiperda Sf9 cell line is a heterogeneous population of rhabdovirus-infected and virus-negative cells: Isolation and characterization of cell clones containing rhabdovirus X-gene variants and virus-negative cell clones","volume":"536","author":"Ma","year":"2019","journal-title":"Virology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pep.2017.11.002","article-title":"Adventitious viruses in insect cell lines used for recombinant protein expression","volume":"144","author":"Geisler","year":"2018","journal-title":"Protein Expr. Purif."},{"key":"ref_110","first-page":"e51112","article-title":"Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system","volume":"81","author":"Margine","year":"2013","journal-title":"J. Vis. Exp."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13036-019-0206-z","article-title":"Process development for pandemic influenza VLP vaccine production using a baculovirus expression system","volume":"13","author":"Lai","year":"2019","journal-title":"J. Biol. Eng."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/biot.201400392","article-title":"Next generation vaccines and vectors: Designing downstream processes for recombinant protein-based virus-like particles","volume":"10","author":"Effio","year":"2015","journal-title":"Biotechnol. J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7774\/cevr.2017.6.1.61","article-title":"Preparation and immunogenicity of influenza virus-like particles using nitrocellulose membrane filtration","volume":"6","author":"Park","year":"2017","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e1800570","DOI":"10.1002\/biot.201800570","article-title":"Membrane-Based Approach for the Downstream Processing of Influenza Virus-Like Particles","volume":"14","author":"Carvalho","year":"2019","journal-title":"Biotechnol. J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/14760584.2019.1704262","article-title":"Advances in influenza virus-like particles bioprocesses","volume":"18","author":"Durous","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Reiter, K., Aguilar, P.P., Grammelhofer, D., Joseph, J., Steppert, P., and Jungbauer, A. (2020). Separation of influenza virus-like particles from baculovirus by polymer grafted anion-exchanger. J. Sep. Sci.","DOI":"10.1002\/jssc.201901215"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/21645515.2015.1032490","article-title":"Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine","volume":"11","author":"Li","year":"2015","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"113577","DOI":"10.1016\/j.ab.2020.113577","article-title":"Development and fit-for-purpose verification of an LC-MS method for quantitation of hemagglutinin and neuraminidase proteins in influenza virus-like particle vaccine candidates","volume":"592","author":"Guo","year":"2020","journal-title":"Anal. Biochem."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/5\/518\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:26:47Z","timestamp":1760174807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/5\/518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":118,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["v12050518"],"URL":"https:\/\/doi.org\/10.3390\/v12050518","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]}}}